本帖最后由 老马 于 2013-3-13 13:43 编辑 5 d# |+ D7 p+ G% T
6 \) n" X1 _& v: X3 ^6 L
健择(吉西他滨)+顺铂+阿瓦斯汀
1 f. i8 e8 |9 |! [. }+ a Gemzar +Cisplatin + Avastin2 U; a. u5 q; Z
http://annonc.oxfordjournals.org/content/21/9/1804.full0 A* V* i( l5 p: v( O* D% o
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" T* Y, t( L- UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. , ?% c1 V1 E7 q1 U( N7 W0 |
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ ]' |. _3 A' Q" `
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 616)
. j8 O% @' S6 g: I华为网盘附件:
) R7 C4 q6 d; `, T/ J7 e【华为网盘】ava.JPG
4 n5 Y2 N9 R) g4 d5 X+ z" R |